Trump threatened "very high" tariffs on Denmark amid Greenland dispute, raising fears of higher prices for Danish pharmaceuticals.

Putting tariffs on Denmark unless it cedes the island of Greenland could hurt access to a few key products, including popular ...

Drug giant Novo Nordisk just reported some clinical trial data. Despite the seemingly good news, the stock crashed right afterward. There's a difference between a clinical success and a ...

Illustration: Elizabeth Smelov Novo Nordisk’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out nearly $100 billion of the drugmaker ...

Novo Nordisk shares fell sharply on Friday as disappointing results from tests of its latest obesity drug wiped about €90 billion off the valuation of Europe’s largest company by market ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Las acciones de la farmaceútuca danesa Novo Nordisk A/S registraron la mayor caída de su historia tras informar resultados decepcionantes de una de las drogas con las que esperaba superar a su ...

Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial disappointed investors hoping for another blockbuster weight-loss drug. The Ozempic-maker's ...

Shares of Novo Nordisk plummeted roughly 20% on Friday. The fall comes after the Danish pharmaceutical giant reported results in a late-stage trial for its experimental CagriSema weight loss drug ...

eller mere - og det sender Novo-aktien ud i en gevaldig nedtur. Men Novo Nordisk har tænkt sig at undersøge midlet nærmere, og det sker i et nyt fase-3 studie. Det skriver Novo Nordisk til Børsen og ...

(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more ...

Bad news for Novo Nordisk (NVO-1.99%) Friday was good news for Eli Lilly (LLY 1.07%) and Viking Therapeutics (VKTX-2.05%), its two main rivals in the field of weight loss drugs. This morning ...